Maat Pharma SA
PAR:MAAT
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
6.48
9.6
|
| Price Target |
|
We'll email you a reminder when the closing price reaches EUR.
Choose the stock you wish to monitor with a price alert.
This alert will be permanently deleted.
Relative Value
The Relative Value of one MAAT stock under the Base Case scenario is 7.32 EUR. Compared to the current market price of 7.82 EUR, Maat Pharma SA is Overvalued by 6%.
Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.
Valuation Multiples
Multiples Across Competitors
MAAT Competitors Multiples
Maat Pharma SA Competitors
| Market Cap | P/S | P/E | EV/EBITDA | EV/EBIT | ||||
|---|---|---|---|---|---|---|---|---|
| FR |
M
|
Maat Pharma SA
PAR:MAAT
|
106.6m EUR | 42.3 | -4.5 | -3.7 | -3.5 | |
| FR |
|
Pharnext SCA
OTC:PNEXF
|
6T USD | 37 797 580.3 | -179 646.3 | -218 147.8 | -215 658.5 | |
| US |
|
Abbvie Inc
NYSE:ABBV
|
320.1B USD | 5.8 | 63 | 15.6 | 24.1 | |
| US |
|
Amgen Inc
NASDAQ:AMGN
|
147.4B USD | 4.5 | 34.9 | 16.5 | 31.3 | |
| US |
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
119.4B USD | 11.2 | -248.8 | 24.8 | 26 | |
| US |
|
Gilead Sciences Inc
NASDAQ:GILD
|
113.8B USD | 4 | 903.4 | 10 | 10 | |
| US |
E
|
Epizyme Inc
F:EPE
|
94.1B EUR | 1 863.9 | -475.6 | -517.9 | -504.1 | |
| AU |
|
CSL Ltd
ASX:CSL
|
135.4B AUD | 5.9 | 33.1 | 20.4 | 25.5 | |
| US |
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
82.6B USD | 6 | 17.8 | 16.2 | 18 | |
| US |
S
|
Seagen Inc
F:SGT
|
39.3B EUR | 18 | -55.1 | -59.2 | -53.4 | |
| NL |
|
argenx SE
XBRU:ARGX
|
34.3B EUR | 18.5 | -130 | -104.6 | -76.2 |
You don't have any saved screeners yet
